Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians - Université de Lorraine Access content directly
Journal Articles European Heart Journal Supplements Year : 2023

Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians

Abstract

The sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce risks of clinical events in patients with heart failure (HF), with early and sustained benefits regardless of ejection fraction, diabetic status, and care setting. As part and parcel of the modern foundational HF therapy, clinicians should be familiar with these drugs, in order to implement their use and limit the potential adverse effects. We present an up-to-date review of current evidence and a practical guide for the prescription of SGLT2 inhibitors in patients with HF, highlighting important elements for patient selection, treatment initiation, dosing, and problem solving.
Fichier principal
Vignette du fichier
suad055.pdf (519 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-04087732 , version 1 (03-05-2023)

Licence

Attribution - NonCommercial

Identifiers

Cite

Luca Monzo, Ilaria Ferrari, Francesco Cicogna, Claudia Tota, Gennaro Cice, et al.. Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians. European Heart Journal Supplements, 2023, 25 (Supplement C), pp.C309 - C315. ⟨10.1093/eurheartjsupp/suad055⟩. ⟨hal-04087732⟩
30 View
34 Download

Altmetric

Share

Gmail Facebook X LinkedIn More